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Abstract
Introduction Delivery of bronchodilators with a metered-dose
inhaler (MDI) and a spacer device in mechanically ventilated
patients has become a widespread practice. However, except
for the short-acting β2-agonist salbutamol, the duration of action
of other bronchodilators, including long-acting β2-agonists,
delivered with this technique is not well established. The
purpose of this study was to examine the duration of
bronchodilation induced by the long-acting β2-agonist
salmeterol administered with an MDI and a spacer in a group of
mechanically ventilated patients with exacerbation of chronic
obstructive pulmonary disease (COPD).
Methods Ten mechanically ventilated patients with acute
exacerbation of COPD received four puffs of salmeterol (25 μg/
puff). Salmeterol was administered with an MDI adapted to the
inspiratory limb of the ventilator circuit using an aerosol cloud
enhance spacer. Static and dynamic airway pressures, minimum
(Rint) and maximum (Rrs) inspiratory resistance, and the
difference between Rrs and Rint (ΔR) were measured before and
at 15, 30, and 60 minutes as well as at 2, 3, 4, 6, 8, 10, and 12
hours after salmeterol administration. The overall effects of
salmeterol on respiratory system mechanics and heart rate
during the 12-hour study period were analyzed by
nonparametric Wilcoxon signed rank test.
Results Salmeterol caused a significant decrease in dynamic
and static airway pressures, Rint, and Rrs. These changes were
evident at 30 minutes and remained significant for 8 hours after
salmeterol administration. The duration of bronchodilation varied
significantly among patients, lasting in some patients more than
10 hours and wearing off in others in less than 6 hours.
Conclusions It is concluded that four puffs of salmeterol
delivered with an MDI and a spacer device induces significant
bronchodilation in mechanically ventilated patients with COPD
exacerbation, the duration of which is highly variable, precluding
definite conclusions in regard to optimum dosing schedules.
Introduction
Delivery of bronchodilators with metered-dose inhalers (MDIs)
in mechanically ventilated patients has become a widespread
practice in recent years [1-6]. Several studies have shown that
MDIs adapted to the inspiratory limb of the ventilator using a
compatible spacer device are as effective as nebulizers
despite a significantly lower dose of bronchodilator adminis-
tered with this technique [1-6]. Compared with the nebulizer,
an MDI has several advantages, such as reliability of dosing,
ease of administration, reduced cost, less personnel time
needed, and lower risk of contamination [7-10]. Although the
technique of administration as well as the dose-response
curve of bronchodilators in mechanically ventilated patients
using an MDI and a spacer device has been examined by sev-
eral studies [1-3,11-15], data in regard to the duration of the
bronchodilator response are scarce and restricted to salbuta-
mol [16,17]. Furthermore, although the bronchodilator
response of long-acting β2-agonists – which are considered
first-line treatment in symptomatic chronic obstructive pulmo-
nary disease (COPD) [18,19] – has been studied in stable
COPD: chronic obstructive pulmonary disease; Crs, st: end-inspiratory static compliance of the respiratory system; HME: heat and moisture 
exchanger; HR: heart rate; MDI: metered-dose inhaler; PaO2: partial pressure of arterial oxygen; Paw: airway pressure; PEEPi: intrinsic positive end-
expiratory pressure; Rint: minimum inspiratory resistance; Rrs: maximum inspiratory resistance; ΔR: difference between maximum inspiratory resistance 
and minimum inspiratory resistance; SaO2: arterial oxygen saturation; VT: tidal volume.Critical Care    Vol 12 No 6    Malliotakis et al.
Page 2 of 7
(page number not for citation purposes)
spontaneously breathing COPD patients [20-23], no data
exist concerning the effect of long-acting β2-agonists in
mechanically ventilated patients with COPD exacerbation. The
purpose of the present study, therefore, was to examine the
duration of bronchodilation induced by the long-acting β2-
agonist salmeterol administered with an MDI and a spacer in a
group of mechanically ventilated patients with COPD.
Materials and methods
Ten male patients (mean age ± standard deviation of 67.8 ± 6
years) with COPD, requiring endotracheal intubation and
mechanical ventilation to manage acute respiratory failure due
to an acute exacerbation of chronic airflow obstruction, were
studied. Patients with a diagnosis of bronchial asthma as well
as patients with pneumonia, pulmonary edema, refractory
hypoxemia, pneumothorax, or excessive airway secretions
were excluded. All patients had a previous diagnosis of COPD
and met established criteria for this diagnosis [18]. Their pre-
vious pulmonary function data were consistent with severe
COPD, with forced expiratory volume in the first second
(FEV1) of 38% ± 4%, forced vital capacity of 56% ± 6%,
residual volume of 177% ± 25%, and total lung capacity of
112% ± 7% of predicted values (mean ± standard error). The
study was approved by the hospital ethics committee, and
informed consent was obtained from the patients' next of kin.
In cases in which patients regained the capacity to give con-
sent, this was later obtained from them.
The patients were studied during a period of clinical stability,
no more than 72 hours after the onset of mechanical ventila-
tion. All patients were orotracheally intubated (low-pressure
cuff endotracheal tube, internal diameter of 8.0 ± 0.5 mm, and
tube length of 28 ± 1 mm), heavily sedated (propofol at a rate
of 4 mg/kg per hour and remifentanyl), and ventilated on vol-
ume-controlled mode (Evita 2; Draeger, Luebeck, Germany)
using settings that minimized dynamic hyperinflation (tidal vol-
ume [VT] of 7 to 8 mL/kg, square wave flow-time profile, no
end-inspiratory pause, and zero external positive end-expira-
tory pressure [PEEPe]) and a fractional concentration of
inspired oxygen that achieved a hemoglobin saturation of
greater than 89%. Minute ventilation was adjusted in each
individual by the attending physician in order to maintain nor-
mal arterial pH and remained constant throughout the study.
The absence of respiratory muscle activity was based on spe-
cific criteria, including absence of negative deflection of airway
pressure (Paw), stabilization of the Paw waveform, constancy
of peak inspiratory pressure from breath to breath, and expo-
nential decline of expiratory flow [24]. Patient characteristics
and baseline ventilator settings are shown in Table 1.
Flow at the airway opening was measured with a heated pneu-
motachograph (Hans-Rudolf 3700; Hans Rudolph, Inc.,
Shawnee, KS, USA) and a differential pressure transducer
(Micro-Switch 140PC; Honeywell Sensing and Control,
Golden Valley, MN, USA) placed between the endotracheal
tube and the Y-piece of the ventilator circuit. Flow was elec-
tronically integrated to provide volume. Paws (Micro-Switch
140PC) were measured from a side port between the pneu-
motachograph and the endotracheal tube. All signals were
sampled at 50 Hz (Windaq, Datac Instruments Inc., Akron,
OH, USA) and stored on a computer disk for later analysis.
Each patient received four puffs of salmeterol. Each puff con-
tained 25 μg of salmeterol xinafoate and was given by an MDI
canister (Serevent inhaler; Glaxo Smith Kline, Uxbridge, Mid-
dlesex, UK) adapted to the inspiratory limb of the ventilator cir-
cuit using an aerosol cloud enhancer spacer (Diemolding
Healthcare Division, Canastota, NY, USA), whereby the MDI
flume is directed away from the patient. The spacer was
placed just before the Y-ventilator connector. The canister was
shaken before each series of puffs. Each puff was delivered at
20- to 30-second intervals, immediately before initiation of air-
flow by the ventilator. Inspiratory flow and VT during adminis-
tration were kept constant to baseline values (Table 1). All
bronchodilators were withheld at least 6 hours before the
study. All patients were receiving corticosteroids (1 mg/kg of
body weight intravenous prednisolone per day) and this regi-
men was not modified during the study. None of the patients
was on theophylline. Arterial blood gases were measured
before and at 4, 8, and 12 hours after drug administration.
Arterial oxygen saturation (SaO2) was measured continuously
using a pulse oxymeter (Critikon, Tampa, FL, USA). All patients
were ventilated in a semirecumbent position (which was kept
constant throughout the study period), certain nursing inter-
ventions (for example, chest physiotherapy and suctioning)
were withheld or minimized, and the remaining aspects of
patient care (for example, fluids and nutrition) were at the dis-
cretion of the treating physician.
Respiratory system mechanics and heart rate (HR) were
assessed before (baseline) and at 15, 30, 60 minutes as well
Table 1
Patient characteristics and baseline ventilator settings
Age, years FiO2 PaO2, mm Hg PaCO2, mm Hg VT, liters Fr, breaths per 
minute
V'I, liters per 
second
TI/TTOT VE, liters per 
minute
67.8 ± 6.0 0.39 ± 0.06 72.8 ± 7.1 59.4 ± 3.8 0.52 ± 0.04 14.6 ± 1.6 0.72 ± 0.04 0.24 ± 0.02 7.5 ± 0.9
Data are presented as mean ± standard deviation. FiO2, fractional concentration of inspired oxygen; Fr, respiratory frequency; PaCO2, partial 
pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; TI/TTOT, duty cycle; VE, minute ventilation; V'I, constant inspiratory 
flow; VT, tidal volume.Available online http://ccforum.com/content/12/6/R140
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as at 2, 3, 4, 6, 8, 10, and 12 hours after each series of puffs.
The mechanical properties of the respiratory system were
determined while the patient was ventilated at baseline venti-
lator settings shown in Table 1 using the occlusion technique,
as previously described [25,26]. End-inspiratory static compli-
ance of the respiratory system (Crs, st) as well as minimum
(Rint) and maximum (Rrs) resistance of the respiratory system
were computed according to standard formulas [25,26]. The
difference between Rrs and Rint (ΔR), caused by time-constant
inequalities and/or viscoelastic behavior (stress relaxation),
was also calculated. Rint and Rrs were corrected for the finite
occlusion time of the occlusion valve of the ventilator [27]. The
endotracheal tube resistance was not taken into account since
each patient served as his or her own control. The heat and
moisture exchanger (HME) of the ventilator circuit was
removed before drug administration and reconnected after
drug delivery, as previously suggested [1]. Similarly, the HME
was removed prior to all respiratory mechanics measurements.
As an index of duration of the resulting bronchodilation, time
after salmeterol administration that Rint remained less than
85% of its baseline value was measured.
Data concerning the overall effects of salmeterol on respira-
tory system mechanics and HR during the 12-hour study
period were analyzed by nonparametric Wilcoxon signed rank
test. Correlation of bronchodilator response to patients' base-
line characteristics as well as their baseline respiratory system
mechanics was tested by linear regression analysis by using
Spearman's correlation coefficients. The changes of postinha-
lational parameters of respiratory system mechanics from
baseline were given in absolute and percentage decrease val-
ues. All results are expressed as mean ± standard deviation. A
P value of less than 0.05 was considered statistically signifi-
cant. The Statistical Package for Social Sciences for Win-
dows version 15.0 (SPSS Inc., Chicago, IL, USA) was used
for data analysis.
Results
Dynamic and static Paws, respiratory system mechanics, and
HR before (time 0) and after salmeterol administration are
shown in Table 2. The administration of 100 μg of salmeterol
caused a significant decrease in dynamic and static Paws as
well as in Rint, Rrs, and intrinsic positive end-expiratory pres-
sure (PEEPi) (Wilcoxon signed rank test). The decrease in Rrs
was due mainly to a decrease in Rint while ΔR remained rela-
tively constant throughout the study period. As shown in Fig-
ures 1 and 2b, the effects of salmeterol on Rint, which reflects
'ohmic' airway resistance, were evident at 30 minutes after
drug delivery and remained relatively constant for approxi-
mately 8 hours. Except for one patient who did not exhibit any
bronchodilator response to salmeterol, in the remaining nine
patients mean Rint changed from baseline by 17.8% ± 5.2% at
30 minutes, reaching a peak decrease of 21.6% ± 2.8% at 2
hours, while at 8 hours after drug administration a significant
decrease of 16.2% ± 6.2% was still present (P < 0.05 for all
values). Individual patient values of Rint at baseline and at the
predefined time points during the 12-hour study period after
salmeterol administration are shown in Figure 3. Duration of
bronchodilator response for each patient, expressed as the
time that individual Rint values remained less than 85% of their
corresponding baseline values, is shown in Figure 4. Of note,
in one patient, a sustained bronchodilator response was still
present at 12 hours whereas four patients still exhibited a sig-
nificant response at 8 hours after salmeterol administration.
Rint remained less than 85% of baseline values for 6 hours in
three patients and for 4 hours in one patient, whereas one
patient did not exhibit any bronchodilator response to salme-
terol. Individual PEEPi and Rrs changes followed the Rint
response in a similar fashion.
Salmeterol administration had no substantial effect on gas
exchange. Partial pressure of arterial oxygen (PaO2) differed
from baseline by 0.9 ± 2.8, 1.3 ± 3.4, and 2.4 ± 4.9 mm Hg at
4, 8, and 12 hours, respectively (P > 0.05 for all values, Wil-
coxon signed rank test), whereas a small (albeit statistically
significant) decrease in PaCO2 (partial pressure of arterial car-
bon dioxide) was noted (-2.8 ± 1.3, -3.7 ± 1.7, and -4.1 ± 2
mm Hg at 4, 8, and 12 hours after salmeterol administration,
respectively, P < 0.05 for all values, Wilcoxon signed rank
test) as the observed bronchodilative effect resulted in
improved alveolar ventilation. Changes in Cst, rs and HR were
not significant at any time interval after salmeterol administra-
tion (Table 2). SaO2 remained constant throughout the study
period, indicating that clinically significant changes in PaO2 as
a result of salmeterol administration did not occur.
Discussion
Our work demonstrates that 100 μg of the long-acting β2-ago-
nist salmeterol delivered by MDI and a spacer caused a sub-
Figure 1
Percentage change (Δ-difference %) in peak airway pressure (Ppk),  minimum inspiratory resistance (Rint), maximum inspiratory resistance  (Rrs), and intrinsic positive end-expiratory pressure (PEEPi) after salme- terol administration Percentage change (Δ-difference %) in peak airway pressure (Ppk), 
minimum inspiratory resistance (Rint), maximum inspiratory resistance 
(Rrs), and intrinsic positive end-expiratory pressure (PEEPi) after salme-
terol administration.Critical Care    Vol 12 No 6    Malliotakis et al.
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stantial bronchodilator effect that induced a significant and
sustained decrease in inspiratory resistance indices, namely a
maximal Rint and Rrs decrease of 21.6% and 16.2%, respec-
tively. These values compare rather well with the correspond-
ing values in previous studies of short-acting β2-agonists in
mechanically ventilated COPD patients, ranging between
18% and 25% for Rint and between 8% and 15% for Rrs [11-
17,28], while baseline respiratory mechanics in these studies
were similar to ours (Rint of 14 to 21 cm H2O/L per second and
Rrs of 20 to 26 cm H2O/L per second). ΔR remained relatively
constant throughout the study, indicating that salmeterol
acted by dilating the central airways in a manner similar to
salbutamol in previous studies [11-17]. Although expiratory
resistance was not measured in the present study, this most
probably was decreased by salmeterol, as indicated by the
significant reduction in PEEPi and end-inspiratory static pla-
teau pressure, which are indirect indices of dynamic hyperin-
flation. Similarly, although lung volumes were not assessed,
the observed reduction in PEEPi could be regarded as an
index – although an indirect one – of a corresponding change
in end-expiratory lung volume (that is, a decrease in dynamic
hyperinflation). We further showed that the onset of the bron-
chodilator response was noted at 30 minutes after drug deliv-
ery while its duration was quite variable among patients,
remaining relatively constant for approximately 6 hours in the
majority of our study population.
It is of interest that the assessment of bronchodilator response
to β2-agonists in mechanically ventilated patients with COPD
exacerbation has been limited mainly to the short-acting β2-
Figure 2
Effect of salmeterol on airway pressures and inspiratory resistance  mean values Effect of salmeterol on airway pressures and inspiratory resistance 
mean values. (a) Mean values (± 1 SD) of peak airway pressure (Ppk) 
and intrinsic positive end-expiratory pressure (PEEPi) at baseline and 
up to 12 hours after salmeterol administration. (b) Mean values (± 1 
SD) of minimum inspiratory resistance (Rint) and maximum inspiratory 
resistance (Rrs) at baseline and up to 12 hours after salmeterol admin-
istration. *Significantly different from baseline values (P < 0.05, Wil-
coxon signed rank test). SD, standard deviation.
Figure 3
Individual patient values of minimum inspiratory resistance (Rint) before  and after salmeterol administration Individual patient values of minimum inspiratory resistance (Rint) before 
and after salmeterol administration. Baseline values (before salmeterol) 
are indicated at time 0. The closed circles connected by the thick solid 
line represent the mean Rint value for the whole patient group. --: 
Patient #1; - -: Patient #2; -x-: Patient #3; - -: Patient #4; - -: Patient 
#5; - -: Patient #6; --: Patient #7; -: Patient #8; --x--: Patient #9; -
-: Patient #10.
Figure 4
Time after salmeterol administration that minimum inspiratory resistance  (Rint) remained less than 85% of baseline in each patient Time after salmeterol administration that minimum inspiratory resistance 
(Rint) remained less than 85% of baseline in each patient.Available online http://ccforum.com/content/12/6/R140
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agonist salbutamol. Although the bronchodilator effect of sal-
meterol has been studied in stable spontaneously breathing
COPD patients [20-23] (where it has been shown to be effec-
tive for up to 12 hours, providing obvious advantages over
short-acting therapies), no data exist concerning the effect of
salmeterol in mechanically ventilated patients with COPD
exacerbation. To the best of our knowledge, this is the first
study about the effect of a long-acting bronchodilator on res-
piratory system mechanics and dynamic hyperinflation in
mechanically ventilated COPD patients.
There are several limitations to our study. Since the optimal
dose of inhaled β2-agonists in mechanically ventilated COPD
patients has not been established clearly and based on the
finding that aerosol deposition in mechanically ventilated
patients is substantially lower than in nonintubated patients,
higher doses have been recommended for ventilated patients
[29]. Subsequent dose-response studies with salbutamol
concluded that a dose of 400 μg ensures the best combina-
tion of bronchodilator effect and safety in mechanically venti-
lated patients with COPD [15,16]. In the case of salmeterol,
however, due to the complete absence of relevant data, a dose
of 100 μg was arbitrarily chosen by extrapolating the results of
the salbutamol dose-response studies, in which the delivered
dose was twice the dose recommended for nonintubated
patients. This, however, does not exclude the possibility that,
in an individual patient, higher doses may be necessary in
order to achieve maximum bronchodilation. For example, it is
not known whether patient 8 would have responded to a
higher dose of salmeterol. Hence, in the absence of dose-
response studies combined with appropriate pharmacokinetic
data in regard to salmeterol administration in mechanically
ventilated patients, straightforward interpretation of our results
is a matter of discussion.
In nonintubated spontaneously breathing COPD patients, 50
μg of salmeterol causes a bronchodilator effect lasting at least
12 hours [20-23]. In the majority of our patients, the observed
bronchodilator effect remained relatively constant for approxi-
mately 6 hours, indicating a reduced duration of the bron-
chodilator response during invasive mechanical ventilation.
This could be explained by the reduced bioavailability of the
drug, as observed by Duarte and colleagues [30] in the case
of salbutamol. Furthermore, reduced duration of bronchodila-
tor effect during COPD exacerbation has been observed for
short-acting β2-agonists [31]. A decrease in pulmonary dispo-
sition and drug absorption in the setting of increased broncho-
motor tone due to airway inflammation has been proposed as
a possible underlying mechanism [32], an observation that
could similarly apply to long-acting β2-agonists.
Table 2
Airway pressures, respiratory system mechanics, and heart rate before and up to 12 hours after salmeterol administration
Baseline 15 
minutes
30 
minutes
1 hour 2 hours 3 hours 4 hours 6 hours 8 hours 10 hours 12 hours
Ppk 35.0 ± 
5.1
33.0 ± 
5.1a
31.4 ± 
5.0a
30.8 ± 
4.8a
30.6 ± 
4.9a
30.4 ± 
4.9a
30.6 ± 
4.5a
30.7 ± 
4.6a
31.4 ± 
4.5a
32.3 ± 
4.5a
33.2 ± 
4.5a
P1 22.3 ± 
4.1
21.4 ± 
4.3a
20.7 ± 
4.4a
20.5 ± 
4.2a
20.4 ± 
4.4a
20.2 ± 
4.1a
20.3 ± 
3.8a
20.4 ± 
3.9a
20.5 ± 
3.6a
20.9 ± 
3.7a
21.4 ± 
3.7a
P2 16.7 ± 
3.1
15.8 ± 
2.8a
15.3 ± 
3.1a
15.1 ± 
2.9a
15.0 ± 
3.1a
14.9 ± 
3.2a
14.9 ± 
2.8a
15.0 ± 
2.8a
15.2 ± 
2.7a
15.5 ± 
2.6a
16.0 ± 
2.7
PEEPi 7.1 ± 1.6 6.2 ± 1.7a 5.5 ± 1.9a 5.2 ± 1.8a 5.2 ± 1.8a 5.1 ± 1.8a 5.1 ± 1.8a 5.2 ± 1.9a 5.4 ± 1.8a 5.7 ± 1.8a 6.2 ± 1.8a
Rrs 25.4 ± 
4.1
23.8 ± 
4.4a
22.3 ± 
4.1a
21.7 ± 
3.6a
21.6 ± 
3.6a
21.5 ± 
3.5a
21.8 ± 
3.3a
21.6 ± 
3.6a
22.5 ± 
4.2a
23.2 ± 
4.1a
23.9 ± 
3.8a
Rint 17.6 ± 
3.7
16.1 ± 
4.0a
14.9 ± 
3.6a
14.3 ± 
3.1a
14.2 ± 
3.0a
14.2 ± 
3.0a
14.3 ± 
3.0a
14.3 ± 
3.0a
15.1 ± 
3.7a
16.0 ± 
3.9a
16.4 ± 
3.4a
ΔR 7.7 ± 2.2 7.7 ± 2.5 7.5 ± 2.2 7.5 ± 2.2 7.5 ± 2.2 7.3 ± 1.9 7.5 ± 1.9 7.3 ± 2.0 7.3 ± 2.0 7.2 ± 2.0 7.5 ± 2.1
Cst, rs 54.3 ± 
9.0
54.2 ± 
9.0
53.1 ± 
7.4
52.3 ± 
7.4
53.0 ± 
7.4
53.3 ± 
7.5
53.1 ± 
7.7
52.7 ± 
6.7
52.8 ± 
6.3
52.2 ± 
5.8
52.2 ± 
5.8
HR 74.8 ± 
8.5
75.0 ± 
7.3
74.5 ± 
6.8
75.0 ± 
7.2
74.5 ± 
6.2
73.9 ± 
7.7
73.5 ± 
8.7
73.1 ± 
9.6
73.8 ± 
8.8
74.8 ± 
11.0
73.4 ± 
10.2
Values are presented as mean ± standard deviation. aSignificantly different from baseline values (P < 0.05, Wilcoxon signed rank test). 
bRespiratory system mechanics were measured while the patients were on volume control with square wave inspiratory flow-time profile. Crs, st, 
end-inspiratory static compliance of the respiratory system (mL/cm H2O); HR, heart rate (beats per minute); P1, airway pressure at the point of 
zero flow (cm H2O); P2, plateau pressure (cm H2O); PEEPi, intrinsic positive end-expiratory pressure (cm H2O); Ppk, peak airway pressure (cm 
H2O); Rint, minimum inspiratory resistance (cm H2O/L per second); Rrs, maximum inspiratory resistance (cm H2O/L per second); ΔR, difference 
between maximum inspiratory resistance and minimum inspiratory resistance (cm H2O/L per second).Critical Care    Vol 12 No 6    Malliotakis et al.
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Propofol has been shown to cause a bronchodilative effect in
mechanically ventilated COPD patients when administered as
a bolus [33]. Although our patients were already receiving a
continuous propofol infusion at a steady dose for at least 24
hours before study inclusion, the possibility of an additive to
salmeterol bronchodilative effect cannot be entirely ruled out.
A considerable degree of variation in regard to the duration
and magnitude of the bronchodilator response was observed.
This response was, furthermore, rather unpredictable. Neither
individual baseline characteristics or respiratory system
mechanics nor the acute bronchodilator response (that is, at
30 minutes after salmeterol administration) was able to predict
the duration of the resulting drug effect. The subject of interin-
dividual variation in bronchodilator response to inhaled β2-
agonists in COPD patients is a well-known entity. This varia-
tion seems to be determined by several factors, like age [34],
the degree of baseline airflow limitation [35], and smoking sta-
tus [36]. Furthermore, a potential role for genetic factors like
polymorphisms of the β2-adrenergic receptor gene in deter-
mining bronchodilator response in COPD patients has
recently been proposed [37]. Although these observations are
limited to short-acting β2-agonists in non-intensive care unit
patients and have to be regarded as preliminary evidence
awaiting confirmation by larger studies, we believe their impli-
cations are nonetheless quite intriguing.
In our study, a 15% decrease of Rint from baseline was defined
as a significant bronchodilative response. Although there are
no established threshold values, previous studies have shown
that an Rrs or Rint decrease of greater than 10% may indicate
significant bronchodilator response [11-17,28]. Dhand and
colleagues [15] examined Rint variability in passively ventilated
COPD patients over the course of 1 hour and found that the
coefficient of variation among patients ranged from 1.6% to
3.9%. Although Rint variability over the course of a 12-hour
period is not known, it seems highly unlikely that a 15%
decrease in Rint would represent merely a patient's airway cal-
iber variability rather than true bronchodilator response.
Therefore, according to our findings, it is not possible to pro-
pose a fixed dosing interval for salmeterol in mechanically ven-
tilated patients with COPD exacerbation. Instead of the use of
a standard dosing regimen, individualization of the dose inter-
val titrated to objective indices of bronchodilation seems to be
more prudent. The issue of objectively guided dose titration is
probably the most important one for the clinician, whereas it
certainly is a matter of debate which indices at which time
point could serve as a reliable marker of effective bronchodila-
tion. As shown in Figure 2a, we observed a decline in peak air-
way pressure (Ppk) of approximately 4 cm H2O at 30 minutes
after drug administration, a change that one could argue is of
clinical relevance and relatively easy to detect at the bedside.
However, further studies designed to specifically address
these particular issues would certainly provide additional
answers.
Conclusion
Our study demonstrated that, in mechanically ventilated
patients with COPD exacerbation, four puffs of salmeterol
delivered by an MDI and a spacer device induced significant
bronchodilation. The duration of the observed bronchodilator
effect was highly variable and unpredictable among patients.
This variability precludes definite guidelines in regard to an
optimum dosing schedule, which should be titrated according
to objective indices of bronchodilation.
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Key messages
￿  In mechanically ventilated patients with chronic obstruc-
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